Clinical Trial Update: EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway [Phase 3]

View source ↗

Summary

Phase 3 study update for setmelanotide in patients with MC4R pathway gene variants; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genetic Obesity
• Obesity

Drugs mentioned

• Setmelanotide (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Obesity, Genetic Obesity | Phase 3 | Status: COMPLETED